Clinical reports of JAK inhibitor treatment for cGVHD
| Reference . | JAK inhibitor . | Study type . | GVHD severity . | Patients . | Prior treatments, median (range) . | Follow-up duration, median (range) . | Response . | OS (95% CI) . |
|---|---|---|---|---|---|---|---|---|
| cGVHD | ||||||||
| Khoury et al67 | Ruxolitinib | Retrospective | Severe | 19 | NA | 18 (6-27) mo | ORR, 89% | NA |
| Zeiser et al68-69 | Ruxolitinib | Retrospective | Moderate or severe | 41 | 3 (1-10) | 22.4 (3-135) wk | ORR, 85% (CR, 7%) | 6 mo, 97% (92%-100%) |
| 24 (NA) mo | Ongoing, 24% | 12 mo, 93% (85%-100%) | ||||||
| Spoerl et al70 | Ruxolitinib | Pilot | Grade 3 | 2 | 4 (3-5) | 23.5 (10-37) wk | Response, 100% | NA |
| Mori et al71 | Ruxolitinib | Retrospective | Severe | 3 | 2 (1-2) | NA | ORR, 100% (CR, 57%) | NA |
| Reference . | JAK inhibitor . | Study type . | GVHD severity . | Patients . | Prior treatments, median (range) . | Follow-up duration, median (range) . | Response . | OS (95% CI) . |
|---|---|---|---|---|---|---|---|---|
| cGVHD | ||||||||
| Khoury et al67 | Ruxolitinib | Retrospective | Severe | 19 | NA | 18 (6-27) mo | ORR, 89% | NA |
| Zeiser et al68-69 | Ruxolitinib | Retrospective | Moderate or severe | 41 | 3 (1-10) | 22.4 (3-135) wk | ORR, 85% (CR, 7%) | 6 mo, 97% (92%-100%) |
| 24 (NA) mo | Ongoing, 24% | 12 mo, 93% (85%-100%) | ||||||
| Spoerl et al70 | Ruxolitinib | Pilot | Grade 3 | 2 | 4 (3-5) | 23.5 (10-37) wk | Response, 100% | NA |
| Mori et al71 | Ruxolitinib | Retrospective | Severe | 3 | 2 (1-2) | NA | ORR, 100% (CR, 57%) | NA |